AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a ...

AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a ...

AbbVie's Q3 earnings will be announced on October 27th. Read why I consider ABBV stock as a de-risked investment opportunity with a generous dividend yield.

AbbVie ABBV will report second-quarter 2022 results on Jul 29, before market open. In the last reported quarter, the company delivered an earnings surprise of 0.32%. AbbVie’s stock has risen 11% ...

AbbVie Stock Trend Bullish Ahead Of Q2 Earnings AbbVie's stock shows a strongly bullish trend, with the share price of $173.15 surpassing its 5, 20, and 50-day exponential moving averages.

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $1.37 billion. The North Chicago, Illinois-based company said it had ...

AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sales rose to $6.97 billion, while Humira declined 29.8%. Oncology and ...

Leerink Partnrs also issued estimates for AbbVie’s Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.33 EPS, FY2026 earnings at $14.01 EPS, FY2028 earnings at $17.67 EPS and FY2029 earnings ...

AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a ...